FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023702303> ?p ?o ?g. }

• W2023702303 abstract "Background: Substantial benefit of trastuzumab is associated with cardiac side effects, mostly asymptomatic. According to current FDA approved package insert, patients should not receive trastuzumab or newer HER2 targeted therapies if there is evidence of cardiomyopathy. Trial design: SAFE-HEaRt is a pilot study evaluating the cardiac safety of trastuzumab, pertuzumab and ado-trastuzumab emtansine in 30 patients with HER2 positive breast cancer (BC) and mild LV dysfunction (LVEF≥40% and Main Eligibility criteria: Patients diagnosed with stage I-IV HER2 positive BC; LVEF≥40% and Specific aims: The primary endpoint is the proportion of patients who complete planned oncologic therapy without the development of a cardiac event (presence of symptoms attributable to heart failure (HF) confirmed by a cardiologist, cardiac arrhythmia requiring pharmacological or electrical treatment, myocardial infarction, sudden cardiac death or death due to myocardial infarct, arrhythmia or HF) or asymptomatic worsening of cardiac function (i.e. asymptomatic decline in LVEF >10% points from baseline and/or LVEF Additional endpoints include: Median time to development of an event; absolute changes in LVEF during HER2 targeted therapy; HER2 therapy holds attributed to cardiotoxicity; correlation of myocardial strain and serum biomarkers with cardiac events and asymptomatic worsening of cardiac function. Statistical methods: A two-stage design is used to test if the completion rate of planned oncologic therapy will be at least 30% versus less than 10% with 80% power at a significance level of 5%. At the first stage, 15 patients will be entered. If one or more patients complete therapy in the absence of a cardiac event, then additional 15 patients will be enrolled in the second stage. Early stopping rules are incorporated for safety based on cardiac death and symptomatic HF. Safety monitoring plan consists of an internal cardiac review panel and a Data Safety Monitoring Board (DSMB) that includes an external cardiologist expert. Present accrual and target accrual: The Institutional Review Board has approved the study. Enrollment of the first patient is expected in July 2013 with a total of 30 patients planned to be recruited. The initial recruitment sites are MedStar Washington Hospital Center and MedStar Georgetown University Hospital. This trial is partially supported by Genentech and funded by a Conquer Cancer Foundation of ASCO Young Investigator Award, supported by The Breast Cancer Research Foundation. Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology, the Conquer Cancer Foundation, or The Breast Cancer Research Foundation. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT1-1-12." @default.
• W2023702303 created "2016-06-24" @default.
• W2023702303 creator A5003348942 @default.
• W2023702303 creator A5018158510 @default.
• W2023702303 creator A5022756369 @default.
• W2023702303 creator A5031050771 @default.
• W2023702303 creator A5043731313 @default.
• W2023702303 creator A5067203408 @default.
• W2023702303 creator A5071176191 @default.
• W2023702303 date "2013-12-15" @default.
• W2023702303 modified "2023-09-25" @default.
• W2023702303 title "Abstract OT1-1-12: SAFE-HEaRt: A pilot study assessing the cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function" @default.
• W2023702303 doi "https://doi.org/10.1158/0008-5472.sabcs13-ot1-1-12" @default.
• W2023702303 hasPublicationYear "2013" @default.
• W2023702303 type Work @default.
• W2023702303 sameAs 2023702303 @default.
• W2023702303 citedByCount "0" @default.
• W2023702303 crossrefType "proceedings-article" @default.
• W2023702303 hasAuthorship W2023702303A5003348942 @default.
• W2023702303 hasAuthorship W2023702303A5018158510 @default.
• W2023702303 hasAuthorship W2023702303A5022756369 @default.
• W2023702303 hasAuthorship W2023702303A5031050771 @default.
• W2023702303 hasAuthorship W2023702303A5043731313 @default.
• W2023702303 hasAuthorship W2023702303A5067203408 @default.
• W2023702303 hasAuthorship W2023702303A5071176191 @default.
• W2023702303 hasConcept C111566952 @default.
• W2023702303 hasConcept C121608353 @default.
• W2023702303 hasConcept C126322002 @default.
• W2023702303 hasConcept C164705383 @default.
• W2023702303 hasConcept C203092338 @default.
• W2023702303 hasConcept C2775935837 @default.
• W2023702303 hasConcept C2776694085 @default.
• W2023702303 hasConcept C2777910003 @default.
• W2023702303 hasConcept C2778198053 @default.
• W2023702303 hasConcept C2778233292 @default.
• W2023702303 hasConcept C2778797674 @default.
• W2023702303 hasConcept C2779786085 @default.
• W2023702303 hasConcept C500558357 @default.
• W2023702303 hasConcept C530470458 @default.
• W2023702303 hasConcept C535046627 @default.
• W2023702303 hasConcept C71924100 @default.
• W2023702303 hasConcept C78085059 @default.
• W2023702303 hasConceptScore W2023702303C111566952 @default.
• W2023702303 hasConceptScore W2023702303C121608353 @default.
• W2023702303 hasConceptScore W2023702303C126322002 @default.
• W2023702303 hasConceptScore W2023702303C164705383 @default.
• W2023702303 hasConceptScore W2023702303C203092338 @default.
• W2023702303 hasConceptScore W2023702303C2775935837 @default.
• W2023702303 hasConceptScore W2023702303C2776694085 @default.
• W2023702303 hasConceptScore W2023702303C2777910003 @default.
• W2023702303 hasConceptScore W2023702303C2778198053 @default.
• W2023702303 hasConceptScore W2023702303C2778233292 @default.
• W2023702303 hasConceptScore W2023702303C2778797674 @default.
• W2023702303 hasConceptScore W2023702303C2779786085 @default.
• W2023702303 hasConceptScore W2023702303C500558357 @default.
• W2023702303 hasConceptScore W2023702303C530470458 @default.
• W2023702303 hasConceptScore W2023702303C535046627 @default.
• W2023702303 hasConceptScore W2023702303C71924100 @default.
• W2023702303 hasConceptScore W2023702303C78085059 @default.
• W2023702303 hasLocation W20237023031 @default.
• W2023702303 hasOpenAccess W2023702303 @default.
• W2023702303 hasPrimaryLocation W20237023031 @default.
• W2023702303 isParatext "false" @default.
• W2023702303 isRetracted "false" @default.
• W2023702303 magId "2023702303" @default.
• W2023702303 workType "article" @default.